L3Harris Technologies heads into the final stretch before its October 29 earnings with a stock down 5% over the past month, a Street that has been cutting targets since July, and sector peers dragging in the same direction.
The price action tells a muddled story. LHX closed at $263.56 on September 1, up a modest 0.5% on the week but still nursing a 4.9% monthly decline. That week-on-week recovery looks less convincing when set against the peer group: RTX fell 2.4% on the week, LMT dropped 2.2%, and NOC slid 1.8%. LHX outperforming this week is partly a function of how far it had already fallen — the stock dropped 10.9% in a single session after its late-July Q2 earnings release, a bruising print that set the tone for everything since.
The most consequential signal right now is what the Street has done with its targets after that July selloff. Analyst activity has run one-way since results: UBS trimmed its target to $298 from $312 while maintaining Neutral, and Susquehanna cut from $410 to $350. More notable was a fresh Jefferies initiation on August 26 — analyst Sheila Kahyaoglu assumed coverage at Hold with a $315 target, stepping in below where many incumbents still sit. The direction is clear: analysts who were enthusiastic in February — JP Morgan went to $395, Morgan Stanley to $390, Citi to $418 — are now well above a stock that has moved sharply lower. The mean price target of $344 implies roughly 30% upside from current levels, which sounds generous but masks the fact that most of those targets were written before the July earnings shock and have only partially adjusted. Valuation has re-rated along with price: the P/E multiple has compressed nearly 3 points over the past 30 days to around 20x, while EV/EBITDA has eased to 13.3x. Neither multiple looks stretched for a defense prime, but neither makes LHX obviously cheap after the recent cuts to growth expectations.
The bull-bear debate hinges on whether the July quarter was an anomaly or a trend. Bulls point to Aerojet segment organic growth near 12%, raised free cash flow guidance of $2.65 billion for FY25, and the durability of defense spending tailwinds. Bears flag the SAS margin compression — down 30 basis points year-on-year to 12.3% — Integrated Mission Systems revenue down 3% reported, and what the company itself flagged as budget timing risks and Space segment softness. The stock's factor scores add nuance: LHX scores in the 95th percentile on dividend quality, and the days-to-cover rank sits at the 77th percentile, pointing to a stock that the broader market treats as fundamentally solid. The short score of 30.6 has drifted marginally lower over the past week, consistent with the low and declining short interest reading of 1.8% of free float — positioning here is not the story.
The lending market confirms that shorts are not pressing. Borrow availability is extremely loose — the 52-week low availability was 2,258%, meaning there has always been an enormous supply of shares relative to demand. Cost to borrow is running near 0.50%, having eased about 7% over the past month. Short interest itself fell nearly 5% on the week to 3.33 million shares. This is not a stock where a short squeeze or borrow squeeze is a live risk; the positioning story is simply benign.
Options lean slightly toward call dominance — the put/call ratio is 0.55, fractionally below its 20-day average of 0.57 and well within normal range at -0.26 standard deviations from the mean. That's a mild tilt toward optimism, though the ratio was running higher (touching 0.69 in late August, the 52-week high) as the July selloff was still fresh. The drift lower in put demand this week suggests traders are no longer actively protecting against a follow-through decline, even as the stock has not reclaimed lost ground.
BlackRock added 1.14 million shares in the most recent reporting period, lifting its stake to 10.2% of shares outstanding — the largest single institutional holder and a meaningful vote of confidence from a passive-leaning buyer with discretion to time its adds. Wellington Management added 313,000 shares, and Boston Partners built 340,000 shares. On the insider front, the most recent SEC filings show only small director stock awards from January 2026; the last meaningful open-market executive transaction was CEO Christopher Kubasik's November 2025 option exercise and planned sale under a 10b5-1 programme — not a discretionary signal.
What to watch next is the October 29 earnings release, where the question is whether the margin pressure and budget timing headwinds flagged in July have stabilised, or whether the SAS and Space segments continue to weigh on the consolidated picture while the Aerojet bright spot holds.
See the live data behind this article on ORTEX.
Open LHX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
